Cholera risk in cities in Uganda: understanding cases and contacts centered strategy (3CS) for rapid cholera outbreak control.
Adolescent
Adult
Age Distribution
Child
Child, Preschool
Cholera
/ epidemiology
Cholera Vaccines
/ administration & dosage
Cities
Cross-Sectional Studies
Disease Outbreaks
/ prevention & control
Drinking Water
/ standards
Female
Humans
Hygiene
/ standards
Male
Middle Aged
Sanitation
/ standards
Sex Distribution
Uganda
/ epidemiology
Young Adult
Africa
Cholera
Kampala
Uganda
chemoprophylaxis
city
infection
outbreak
prevention
treatment
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
01
2021
accepted:
26
06
2021
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
13
10
2021
Statut:
epublish
Résumé
in the recent past, cities in sub-Saharan Africa have reported serious cholera outbreaks that last for several months. Uganda is one of the African countries where cities are prone to cholera outbreaks. Studies on cholera in Bangladesh show increased risk of cholera for the immediate household members (contacts) yet the control interventions mainly target cases with little or no focus on contacts. This study aimed to describe the rapid control of cholera outbreaks in Kampala and Mbale cities, Uganda, using, "Cases and Contacts Centered Strategy (3CS)" that consisted of identification and treatment of cases, promotion of safe water, sanitation, hygiene (WaSH) and selective chemoprophylaxis for the contacts. a cross-sectional study was conducted in 2015-2016 in the Kampala and Mbale cities during cholera outbreaks. Cholera cases were treated and 816 contacts from 188 households were listed and given cholera preventive packages. Data were collected, cleaned, analysed and stored in spreadsheet. Comparison of categories was done using Chi-Square test. a total of 58 and 41 confirmed cholera cases out of 318 and 153 suspected cases were recorded in Kampala and Mbale cities respectively. The outbreaks lasted for 41 days in both cities. Case fatality rates were high; 12.1% (5/41) for Mbale city and 1.7% (1/58) for Kampala city. Fifty-five percent (210/379) of stool samples were tested by culture to confirm V. choleraeO1. No contacts listed and given cholera preventive package developed cholera. Both sexes and all age groups were affected. In Kampala city, the males were more affected than the females in the age groups less than 14 years, p-value of 0.0097. this study showed that by implementing 3CS, it was possible to rapidly control cholera outbreaks in Kampala and Mbale cities and no cholera cases were reported amongst the listed household contacts. The findings on 3CS and specifically, selective antibiotic chemoprophylaxis for cholera prevention, could be used in similar manner to oral cholera vaccines to complement the core cholera control interventions (disease surveillance, treatment of cases and WaSH). However, studies are needed to guide such rollout and to understand the age-sex differences in Kampala city.
Identifiants
pubmed: 34603574
doi: 10.11604/pamj.2021.39.193.27794
pii: PAMJ-39-193
pmc: PMC8464210
doi:
Substances chimiques
Cholera Vaccines
0
Drinking Water
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
193Informations de copyright
Copyright: Godfrey Bwire et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Lancet. 1998 Nov 14;352(9140):1570
pubmed: 9843100
Afr Health Sci. 2012 Dec;12(4):579-83
pubmed: 23516123
BMC Public Health. 2020 Jul 17;20(1):1128
pubmed: 32680495
East Afr Med J. 2000 Jul;77(7):347-9
pubmed: 12862150
BMC Infect Dis. 2020 Mar 18;20(1):226
pubmed: 32183745
BMJ Open. 2013 Apr 03;3(4):
pubmed: 23558731
BMC Public Health. 2017 Jul 18;18(1):30
pubmed: 28720083
Lancet. 2009 Mar 21;373(9668):993-4
pubmed: 19330941
MMWR Morb Mortal Wkly Rep. 2018 May 18;67(19):556-559
pubmed: 29771877
PLoS Negl Trop Dis. 2016 May 17;10(5):e0004679
pubmed: 27186885
PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006118
pubmed: 29284003
Neth J Med. 2014 Nov;72(9):442-8
pubmed: 25387613
Afr Health Sci. 2006 Jun;6(2):93-7
pubmed: 16916299
PLoS Negl Trop Dis. 2013 Dec 05;7(12):e2545
pubmed: 24340106
PLoS Negl Trop Dis. 2018 Jul 27;12(7):e0006641
pubmed: 30052631
J Infect Dis. 2013 Nov 1;208 Suppl 1:S78-85
pubmed: 24101649
Infect Dis Poverty. 2017 Oct 10;6(1):146
pubmed: 28992811
Clin Infect Dis. 2009 Nov 15;49(10):1473-9
pubmed: 19842974
PLoS One. 2018 Jun 27;13(6):e0198431
pubmed: 29949592
J Infect Dev Ctries. 2009 Mar 01;3(2):148-51
pubmed: 19755746
Emerg Infect Dis. 2012 Sep;18(9):1480-3
pubmed: 22931687
PLoS Negl Trop Dis. 2017 Mar 13;11(3):e0005407
pubmed: 28288154
Vaccine. 2020 Feb 29;38 Suppl 1:A31-A40
pubmed: 31395455
Emerg Infect Dis. 2017 Dec;23(13):
pubmed: 29155665
BMC Infect Dis. 2019 Jun 11;19(1):516
pubmed: 31185939